ValueQ4, 24TTMSelling/general/admin expenses——Research & development——Operating income-139.9 M-334.9 MNon-Operating Income, Total——Interest expense, net of interest capitalized——Non-Operating Income, excl. Interest Expenses——Unusual income/expense——Pretax income121.15 M1.69 BEquity in earnings——Taxes11.5 M22 MNon-controlling/minority interest——After tax other income/expense——Net income before discontinued operations109.65 M1.67 BDiscontinued operations——Net income109.65 M1.67 BDilution adjustment——Preferred dividends——Diluted net income available to common stockholders109.65 M1.67 BBasic earnings per share (Basic EPS)——Diluted earnings per share (Diluted EPS)0.497.58Average basic shares outstanding222.62 M874.05 MDiluted shares outstanding224.72 M884.78 MEBITDA——EBIT——Cost of revenue——Other cost of goods sold——Depreciation & amortization (cash flow)84.9 M376.8 M
Qiagen N.V
QIAGEN N.V. is a German-founded multinational provider of sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical research. The company operates in more than 35 offices in over 25 countries. QIAGEN N.V., the global corporate headquarter of the QIAGEN group, is located in Venlo, The Netherlands. The main operative headquarters are located in Hilden, Germany. European, American, Chinese, and Asian-Pacific regional headquarters are located respectively in Hilden, Germany; Germantown, Maryland, United States; Shanghai, China; and Singapore. QIAGEN's shares are listed at the NYSE and at the Frankfurt Stock Exchange in the Prime Standard. Thierry Bernard is the company's Chief Executive Officer.